- SPACs
- Big Cypress Acquisition Corp.
Big Cypress Acquisition Corp.
Completed 2021-10-22- CIK 1833214
- BCYP
- Now SABS
- IPO 2021-01-12
- $116M trust
- 436 filings
Successfully merged with SAB Biotherapeutics, Inc. • Now trading as SABS
- IPO Size
- $115M
- raised at the IPO
- Trust
- $116M
- as of 2021-09-30
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2021
- year it listed
Filings, by quarter
436 filings over 25 quarters; violet bars carry a milestone
- 20 Q4: 2 filings
- 21 Q1: 24 filings
- 21 Q2: 9 filings
- 21 Q3: 32 filings
- 21 Q4: 63 filings
- 22 Q1: 15 filings
- 22 Q2: 14 filings
- 22 Q3: 19 filings
- 22 Q4: 12 filings
- 23 Q1: 23 filings
- 23 Q2: 23 filings
- 23 Q3: 14 filings
- 23 Q4: 37 filings
- 24 Q1: 18 filings
- 24 Q2: 10 filings
- 24 Q3: 15 filings
- 24 Q4: 3 filings
- 25 Q1: 4 filings
- 25 Q2: 4 filings
- 25 Q3: 22 filings
- 25 Q4: 19 filings
- 26 Q1: 26 filings
- 26 Q2: 10 filings
- 26 Q3: 12 filings
- 26 Q4: 6 filings
- S-1 filed 20 Q4
- IPO 21 Q1
- Definitive agreement 21 Q2
- Completed 21 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
- Registration2020-12-07 Filed S1
- IPO2021-01-12 IPO, search begins
- Definitive Agreement2021-06-21 Agreement for merger
- Completed2021-10-22 Merger Completed
About
Big Cypress Acquisition Corp. is a blank-check company seeking a business combination; it intends to focus on life science companies in the United States and Israel.
Investment Focus
Biopharmaceuticals
Geographic Focus
United States, Israel
Key Information
As the filings state it
- IPO Date
- 2021-01-12
- Total Redemptions
- $81.1M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2021-10-22
- Merger Target
- SAB Biotherapeutics, Inc.
- SPAC Ticker
- BCYP
- Merged Ticker
- SABS
Stock Performance
SABSTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2021-02-09 | $10.22 | |
| At Merger | 2021-10-25 | $7.30 | -29% |
| 6 Months Post-Merger | 2022-04-25 | $2.66 | -64% |
| 1 Year Post-Merger | 2022-10-24 | $0.76 | -90% |
| 2 Years Post-Merger | 2023-10-23 | $0.97 | -87% |
| Current Price | 2026-11-18 | $3.20 | -69% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The management team reports more than 150 years of combined experience operating and investing in life science companies, and has collectively closed more than 50 mergers and acquisitions.